Tocris Bioscience™ Molnupiravir

Catalog No.	Quantity
75-861-0	10 mg
75-865-0	50 mg

Catalog No. 75-861-0 Supplier Tocris Bioscience™ Supplier No. 7586/10

Description

Prodrug of antiviral nucleoside analog; inhibits SARS-CoV, SARS-CoV-2 and MERS-CoV infection

Molnupiravir is a broad-spectrum antiviral prodrug of the nucleoside analog β-D-N4-hydroxycytidine (NHC). Molnupiravir competes predominantly with CTP for incorporation; it induces lethal viral mutagenesis by increasing G to A and C to U transition mutations without inhibition of RNA synthesis in replicating coronaviruses, which prevents the development of viral resistance. In primary airway epithelial cell cultures, Molnupiravir dose-dependently inhibits SARS-CoV-2 infectious virus production; it also inhibits MERS-CoV and SARS-CoV with EC50 values in the submicromolar range. In mice infected with SARS-CoV or MERS-CoV, Molnupiravir improves pulmonary function, and reduces virus titer and body weight loss. Molnupiravir also displays in vivo efficacy against seasonal and pandemic influenza A shed virus. It is orally bioavailable.

Specifications

• Chemical Name or Material: β-D-N4-hydroxycytidine-5 '-isopropyl ester
• CAS: 2492423-29-5
• Quantity: 10 mg
• Target: Antiviral Compounds
• Molecular Formula: C₁₃H₁₉N₃O₇
• Purity: 98%